(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/208092 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/4985* (2006.01)
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/CN2023/091076

(22) International Filing Date:
27 April 2023 (27.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2022/000075
28 April 2022 (28.04.2022) CN
PCT/CN2022/131223
10 November 2022 (10.11.2022) CN
PCT/CN2022/135765
01 December 2022 (01.12.2022) CN
PCT/CN2023/089128
19 April 2023 (19.04.2023) CN

(71) Applicant: **DANATLAS PHARMACEUTICALS CO., LTD.** [CN/CN]; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN).

(72) Inventors: **ZHUO, Jincong**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **ZHANG, Yao**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **ZHOU, Wenlai**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **YU, Zhangqi**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN). **YAN, Dan**; Suite 101, Floor 2, Building 2-4A, 7#, Liangshuihe 1st Street, BDA, Daxing District, Beijing 100176 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF

(57) Abstract: The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.



(I).

WO 2023/208092 A1